[2014] Bile acid sequestrants (anion exchange resins) for preventing CVD 1.4.47 Do not offer a bile acid sequestrant (anion exchange resin) for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes. [2014] Omega-3 fatty acid compounds for preventing CVD 1.4.48 Do not offer omega-3 fatty acid compounds for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes. Icosapent ethyl is an exception to this if used as described in NICE's technology appraisal guidance on icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. 1.4.49 Tell people that there is no evidence that use of omega-3 fatty acid compounds help prevent CVD, except use of icosapent ethyl as described in NICE's technology appraisal guidance on icosapent ethyl with statin therapy. [2014] Combination therapy for preventing CVD 1.4.50 For the primary or secondary prevention of CVD, do not offer the combination of a statin with: a bile acid sequestrant (anion exchange resin), a fibrate or nicotinic acid, or an omega 3 fatty acid compound, except icosapent ethyl as described in NICE's technology appraisal guidance on icosapent ethyl with statin therapy. Ezetimibe 1.4.51 People with primary hypercholesterolaemia should be considered for ezetimibe treatment in line with NICE's technology appraisal guidance on ezetimibe for treating primary heterozygous-familial and non-familial Other treatment options For other treatment options, see the NICE technology appraisal guidance on our topic page on lipid disorders. 